

## WHAT IS CLAIMED IS:

1. A method of promoting viability of a transplant cell population comprising contacting the transplant cell population with an effective amount of a compound  
5 selected from the group consisting of a hydrophilic bile acid, a salt thereof, an analog thereof, and a combination thereof.
2. The method of claim 1 wherein cells of the transplant cell population are differentiated cells.  
10
3. The method of claim 1 wherein cells of the transplant cell population are precursor cells.
4. The method of claim 1 wherein the contacting occurs *in vitro*.  
15
5. The method of claim 1 wherein the contacting occurs *in vivo*.
6. The method of claim 5 wherein the contacting occurs in a donor of the transplant cell population.  
20
7. The method of claim 1 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population with the compound prior to transplanting the transplant cell population in a subject.
- 25 8. The method of claim 7 wherein the subject is a human.
9. The method of claim 7 further comprising treating the subject with the compound.
- 30 10. The method of claim 9 wherein treating the subject with the compound comprises administering the compound to the subject prior to transplanting the transplant cell population in the subject.

11. The method of claim 10 wherein treating the subject with the compound comprises administering the compound to the subject after transplanting the transplant cell population in the subject.
- 5
12. The method of claim 9 wherein treating the subject with the compound comprises administering the compound to the subject after transplanting the transplant cell population in the subject.
- 10
13. The method of claim 9 wherein treating the subject comprises treating the subject parenterally with the compound.
14. The method of claim 9 wherein treating the subject comprises treating the subject orally with the compound.
- 15
15. The method of claim 1 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.
- 20
16. The method of claim 1 wherein the cells of the transplant cell population comprise autologous cells, heterologous cells, or xenologous cells.
17. The method of claim 1 wherein the cells of the transplant cell population comprises at least a portion of autologous tissue, heterologous tissue, or xenologous
- 25
- tissue.
18. The method of claim 1 wherein the transplant cell population is an organ.
19. The method of claim 18 wherein the organ is a liver, a kidney, a heart, a lung, or
- 30
- a pancreas.

20. The method of claim 18 further comprising treating the subject with the compound after transplanting the transplant cell population in the subject.
21. The method of claim 1 further comprising treating a subject with the compound  
5 after transplanting the transplant cell population in the subject.
22. A method for treating a human having Parkinson's disease, the method comprising contacting a transplant cell population *in vitro* with an effective amount of tauroursodeoxycholic acid in combination with a pharmaceutically acceptable carrier,  
10 wherein the transplant cell population are differentiated cells; and  
transplanting the transplant cell population into the human.
23. A method for treating a subject having Parkinson's disease, the method comprising contacting a transplant cell population with an effective amount of a  
15 compound selected from the group consisting of ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof to promote viability of the transplant cell population; and  
transplanting the transplant cell population into a subject.
- 20 24. The method of claim 23 wherein the ursodeoxycholic acid analog includes a conjugated derivative.
25. The method of claim 24 wherein the conjugated derivative is tauroursodeoxycholic acid.  
25
26. The method of claim 23 wherein the subject is a human.
27. The method of claim 23 wherein the cells are differentiated cells.
- 30 28. The method of claim 23 wherein the cells are precursor cells.

29. The method of claim 23 wherein the contacting occurs *in vitro*.
30. The method of claim 23 wherein the contacting occurs *in vivo*.
- 5 31. The method of claim 30 wherein the contacting occurs in a donor of the transplant cell population.
32. The method of claim 23 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population with the compound  
10 prior to transplanting the transplant cell population in the subject.
33. The method of claim 32 further comprising treating the subject with the compound.
- 15 34. The method of claim 33 wherein treating the subject with the compound comprises administering the compound to the subject prior to transplanting the cells in the subject.
35. The method of claim 34 wherein treating the subject with the compound  
20 comprises administering the compound to the subject after transplanting the cells in the subject.
36. The method of claim 33 wherein treating the subject with the compound  
25 comprises administering the compound to the subject after transplanting the cells in the subject.
37. The method of claim 23 wherein treating the subject comprises treating the subject parenterally with the compound.
- 30 38. The method of claim 23 wherein treating the subject comprises treating the subject orally with the compound.

39. The method of claim 23 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.
- 5 40. The method of claim 23 wherein the cells comprise autologous cells, heterologous cells, or xenologous cells.
41. The method of claim 23 wherein the cells comprises at least a portion of autologous tissue, heterologous tissue, or xenologous tissue.
- 10 42. A method, comprising:  
treating a donor of a transplant cell population with a compound selected from the group consisting of a hydrophilic bile acid, a salt thereof, an analog thereof, and a combination thereof.
- 15 43. The method of claim 42 wherein the hydrophilic bile acid comprises ursodeoxycholic acid, and treating the donor comprises treating the donor with the ursodeoxycholic acid.
- 20 44. The method of claim 42 wherein the hydrophilic bile acid comprises tauroursodeoxycholic acid, and treating the donor comprises treating the donor with the tauroursodeoxycholic acid.
- 25 45. The method of claim 42 wherein the donor of the transplant cell population is living.
46. The method of claim 42 wherein treating the donor comprises treating the donor with the compound before removal of the transplant cell population from the donor.
- 30 47. The method of claim 42 wherein treating the donor comprises treating the donor with the compound during removal of the transplant cell population from the donor.

48. The method of claim 42 wherein treating the donor comprises treating the donor with the compound after removal of the transplant cell population from the donor.
- 5 49. The method of claim 42 wherein the transplant cell population is at least a portion of an organ of the donor.
50. The method of claim 49 wherein the at least a portion of the organ is the entire organ of the donor.
- 10 51. The method of claim 42 wherein treating the donor comprises treating the donor parenterally with the compound.
52. The method of claim 42 wherein treating the donor comprises treating the donor orally with the compound.
- 15 53. The method of claim 42 wherein treating the donor with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.
- 20 54. A method, comprising:  
treating a subject for a transplant cell population with a compound selected from the group consisting of a hydrophilic bile acid, a salt thereof, an analog thereof, and a combination thereof.
- 25 55. The method of claim 54 wherein the hydrophilic bile acid comprises ursodeoxycholic acid, and treating the subject comprises treating the subject with the ursodeoxycholic acid.
- 30 56. The method of claim 54 wherein the hydrophilic bile acid comprises tauroursodeoxycholic acid, and treating the subject comprises treating the subject with the tauroursodeoxycholic acid.

57. The method of claim 54 wherein treating the subject comprises treating the subject with the compound before transplanting the transplant cell population into the subject.

5

58. The method of claim 54 wherein treating the subject comprises treating the subject with the compound during transplanting the transplant cell population into the subject.

10 59. The method of claim 58 wherein treating the subject comprises treating the transplant cell population in the subject.

15 60. The method of claim 54 wherein treating the subject comprises treating the subject with the compound after transplanting the transplant cell population into the subject.

61. The method of claim 54 wherein the transplant cell population is at least a portion of an organ.

20 62. The method of claim 61 wherein the at least a portion of the organ is the entire organ.

63. The method of claim 54 wherein treating the subject comprises treating the subject parenterally with the compound.

25

64. The method of claim 54 wherein treating the subject comprises treating the subject orally with the compound.

30 65. The method of claim 54 wherein treating the subject with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.